LINDSAY GRAY: Open Payments
NPI 1508407594 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 35 payments from 17 companies in 2025. Trend: 2023 $558 · 2024 $759 · 2025 $984
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 5 | $146 |
| Alexion Pharmaceuticals, Inc. | 1 | $135 |
| Apellis Pharmaceuticals, Inc. | 3 | $119 |
| Novartis Pharmaceuticals Corporation | 3 | $98 |
| Amgen Inc. | 4 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| Calliditas Therapeutics US Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Outset Medical Inc | 1 | $36 |
Products named: ULTOMIRIS, Filspari, Fabhalta, KRYSTEXXA, DUPIXENT, Kerendia, TARPEYO, JYNARQUE.
Industry payments across NV — which companies pay providers there.
